Ethyl hydrogen (4-{[4-({2-(diethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → ethyl hydrogen (4-{[4-({6-[1-(3-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 3A using diethyl (4-{[4-({6-[1-(3-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate (Compound 20B). 1H NMR (CD3OD, 400 MHz): δ=9.20 (br. s., 1H), 8.51 (br. s., 1H), 8.34 (s, 1H), 8.25 (s, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.42 (br. s., 2H), 7.35 (d, J=6.6 Hz, 2H), 4.29 (dd, J=6.6, 13.6 Hz, 1H), 4.15-4.04 (m, 1H), 3.85 (t, J=6.9 Hz, 2H), 3.48 (d, J=5.3 Hz, 2H), 3.05-2.91 (m, 5H), 2.33-2.22 (m, 1H), 1.14 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.8 Hz, 3H). MS (ESI): m/z=649.70 [M+H]+. UPLC: tR=1.13 min (UPLC-SQD: analytical—2 min).

Provenance & Evidence